Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer

This study has been terminated.
(lack of sufficient accrual)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: July 5, 2000
Last updated: May 1, 2013
Last verified: June 2011
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: February 2003
  Primary Completion Date: December 2002 (Final data collection date for primary outcome measure)
Clark JW, Niedzwiecki D, Hollis D, et al.: Phase II trial of 5-fluororuacil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzamab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-3584, 2003.